British Biotech Pharmaceuticals Limited

Philip Huxley

Andrew Paul Ayscough

Alan Hastings Drummond

Lindsey Ann Pearson

Andrew Miller

Zoe Marie Spavold

Fionna Mitchell Martin

Cytostatic agents

The present invention provide compounds exemplified by 2(R or S)-&lsqb;2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methyl-pentanoylamine&rsqb;-2-phenyl-ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-phenylethanoic acid isopropyl ester; 2(R or S)-&lsqb;2R-(S-Hydroxycarbamoyi-methoxy-methyl)-4-methyl-pentanoylamino&rsqb;-3-phenylethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(4-methoxyphenyl)ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-2-yl)ethanoic acid cyclopentyl ester; and 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-3-yl)ethanoic acid cyclopentyl ester are cytostatic agents. Methods of treating proliferative cell growth disorders as well a methods of inhibiting hyper-proliferative cells are also disclosed.

Matrix metalloproteinase inhibitors

Growing community of inventors

Oxford, United Kingdom

Philip Huxley